Olmesartan Medoxomil Accord

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil Accord, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Olmesartan Medoxil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Medoxil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

- Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with type 2 diabetes. - Heart failure: used as part of combination therapy to improve symptoms and outcomes.

Olmesartan Medoxil Accord may cause a range of adverse reactions.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion - Diarrhea - Cough

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hyperkalemia - Liver enzyme elevations - Allergic skin reactions such as Stevens‑Johnson syndrome

When prescribing Olmesartan Medoxil Accord, clinicians should consider several safety aspects.

- Monitor blood pressure: ensure adequate control without excessive lowering. - Assess renal function: check serum creatinine and eGFR before initiation and periodically. - Check electrolytes: especially potassium levels, to avoid hyper‑kalaemia. - Avoid in pregnancy: drug is contraindicated in the second and third trimesters. - Use cautiously in hepatic ​   - Store at ambient temperature: keep   - Keep   -  

Olmes-

---